Logo

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Share this
Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Shots:

  • The CHMP’s recommendation is based on P-III True North study evaluating Zeposia as an induction and maintenance therapy vs PBO in adult patients with moderately to severely active UC
  • The study demonstrated improvements across all 1EPs and 2EPs including clinical remission- clinical response- endoscopic improvement and endoscopic histologic mucosal improvement @10 & 52wks.
  • If approved by the EC- Zeposia will become the first and only oral sphingosine 1-phosphate (S1P) receptor modulator approved for UC in the EU

Click here to­ read full press release/ article | Ref: BMS | Image: BMS


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family